Patents Assigned to Altor Bioscience, LLC
  • IL-15-based fusions to IL-7 and IL-21
    Patent number: 11965007
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: April 23, 2024
    Assignee: Altor Bioscience, LLC.
    Inventor: Hing C. Wong
  • Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex
    Patent number: 11925676
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: March 12, 2024
    Assignee: Altor Bioscience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Method of treating cancer with composition comprising IL-15-based molecules and BCG
    Patent number: 11890323
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 6, 2024
    Assignee: Altor Bioscience, LLC
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • IL-15-based fusions to IL-12 and IL-18
    Patent number: 11872272
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: January 16, 2024
    Assignee: Altor Bioscience, LLC
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
  • Multimeric IL-15 soluble fusion molecules and methods of making and using same
    Patent number: 11845783
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: December 19, 2023
    Assignee: Altor Bioscience, LLC.
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
  • IL-15-based molecules and methods of use thereof
    Patent number: 11679144
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: June 20, 2023
    Assignee: Altor Bioscience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Fusion molecules and IL-15 variants
    Patent number: 11673932
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: June 13, 2023
    Assignee: Altor Bioscience, LLC.
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
  • IL-15-based fusions to IL-12 and IL-18
    Patent number: 11612645
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: March 28, 2023
    Assignee: Altor Bioscience, LLC
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
  • IL-15-based fusions to IL-12 and IL-18
    Patent number: 11571470
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: February 7, 2023
    Assignee: Altor Bioscience LLC
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
  • Fusion molecules and IL-15 variants
    Patent number: 11498950
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: November 15, 2022
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
  • IL-15-based molecules and methods of use thereof
    Patent number: 11471511
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 18, 2022
    Assignee: Altor Bioscience, LLC
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Multimeric IL-15-based molecules
    Patent number: 11369679
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: June 28, 2022
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robert Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
  • Interleukin 15 (IL-15) variants
    Patent number: 11365231
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 21, 2022
    Assignee: Altor BioScience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
  • Multimeric IL-15-based molecules
    Patent number: 11318201
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: May 3, 2022
    Assignee: Altor Bioscience, LLC.
    Inventors: Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robert G. Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
  • Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors
    Patent number: 11261231
    Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: March 1, 2022
    Assignees: Altor BioScience, LLC., The Regents of the University of Califoria
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • Multimeric IL-15-based molecules
    Patent number: 11197929
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: December 14, 2021
    Assignees: NantCell, Inc., Altor BioScience, LLC.
    Inventors: Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robert G. Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
  • IL-15-based molecules and methods of use thereof
    Patent number: 11173191
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 16, 2021
    Assignee: Altor Bioscience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
    Patent number: 11168138
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant, a cytokine receptor or cytokine ligand, and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 9, 2021
    Assignee: Altor Bioscience, LLC
    Inventors: Qiongzhen Li, Xiaoyun Zhu, Hing C. Wong
  • IL-15-based fusions to IL-7 and IL-21
    Patent number: 11161890
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 2, 2021
    Assignee: Altor Bioscience LLC.
    Inventor: Hing C. Wong
  • IL-15-based fusions to IL-12 and IL-18
    Patent number: 11129883
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 28, 2021
    Assignee: Altor BioScience, LLC.
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong